RTI Biologics, maker of orthopedic and other biologic implants, posted record revenues of $42.8 million for the third quarter, an 11 percent increase over the same period last year, according to a release from RTI Biologics.
Domestic revenues were $37.4 million for the third quarter and $105.4 million for the first nine months of 2009, both representing increases of 12 percent over the same periods the year before.
Third-quarter revenues reflect the launch of four new orthopedic implants and revenue for the first nine months reflects new revenues from Tutogen, which merged with RTI.
Read the release on RTI Biologics third-quarter revenue.
From findings on cervical disc replacement to total knee replacement, Becker’s reported on eight spine and orthopedic studies since March…
Researchers at UMass Chan Medical School in Worcester, Mass., have created an algorithm to predict total knee replacement outcomes in…
Orthopaedic Solutions Management has acquired Orlando Hand Surgical Associates, marking its eighth acquisition. OHSA was founded in 2000 and has…
Comments are closed.